Literature DB >> 6153509

Peripapillary neovascular membranes in presumed ocular histoplasmosis.

H L Cantrill, D Burgess.   

Abstract

We studied 39 eyes with ocular histoplasmosis and peripapillary neovascular membranes for an average of 12 months. On the basis of clinical findings, 19 were selected for treatment with photocoagulation. Of the treated eyes, 12 (63%) had a visual result of 6/12 (20/40) or better. Of the 20 untreated eyes, six were clinically untreatable and 14 were electively followed up. All but one of the eyes electively followed up had a good visual result. Proximity of the neovascular membrane to the fovea was the most important prognostic factor in determining visual outcome. All eyes with membranes less than 1/4 disk diameter from the fovea lost central vision. All membranes greater than one disk diameter had excellent results. The indications for treatment were prolonged serous or hemorrhagic detachment of the fovea, documented progression of the membrane, and possibly, loss of central vision in the fellow eye from peripapillary disease. Residual and recurrent neovascularization were significant treatment complications.

Entities:  

Mesh:

Year:  1980        PMID: 6153509     DOI: 10.1016/0002-9394(80)90111-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  Krypton red laser photocoagulation of peripapillary subretinal neovascular membranes.

Authors:  W H Annesley; H G Shah; A M Mansour; W L Decker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

2.  Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in an elderly UK population-the Bridlington eye assessment project (BEAP): a cross-sectional study (2002-2006).

Authors:  Craig Wilde; Ali Poostchi; Rajnikant L Mehta; Jonathan G Hillman; Hamish K MacNab; Marco Messina; Gaspare Monaco; Stephen A Vernon; Winfried M Amoaku
Journal:  Eye (Lond)       Date:  2018-10-12       Impact factor: 3.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.